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Abstract
Background: Naltrexone is an effective medication for treatment of alcohol dependence, but its
efficacy is limited by lack of adherence to the oral dosage form. A long-acting depot formulation of
naltrexone may increase adherence.
Methods: A single site, 6-week open label study was conducted with 16 alcohol dependent
subjects each receiving 300 mg of Naltrexone Depot by intramuscular injection. The main
outcomes were safety and tolerability of the Naltrexone Depot formulation, blood levels of
naltrexone and its main metabolite 6-beta naltrexol, and self-reported alcohol use. All subjects
received weekly individual counseling sessions.
Results: The medication was well tolerated with 88% of subjects completing the 6-week trial. The
most common side effect experienced was injection site complications. There were no serious
adverse events. Subjects had naltrexone and 6-beta-naltrexol concentrations throughout the trial
with mean values ranging from 0.58 ng/mL to 2.04 ng/mL and 1.51 ng/mL to 5.52 ng/mL,
respectively, at each sampling time following administration. Compared to baseline, subjects had
significantly reduced number of drinks per day, heavy drinking days and proportion of drinking days.
Conclusion: Naltrexone Depot is safe and well tolerated in alcoholics and these findings support
the further investigation of its utility in larger double-blind placebo controlled trials.
Background
Naltrexone is an opiate receptor antagonist that was
approved in 1984 for the treatment of opiate dependence.
The safety and efficacy of naltrexone in reducing alcohol
consumption were established in controlled clinical trials
[1,2] which led, in 1994, to United States Food and Drug
Administration (FDA) approval of a 50 mg oral tablet for
treatment of alcohol dependence. Since receiving FDA
approval, several studies on naltrexone's effectiveness in
reducing alcohol consumption have been conducted. Nal-
trexone has demonstrated effects on drinking behavior in
alcoholics through reducing alcohol use among subjects
who sample alcohol as well as promotion of alcohol
abstinence [3-5]. One study that used cognitive behavior
therapy and random assignment to oral naltrexone or pla-
cebo in recently abstinent alcoholics found that 62% of
the naltrexone group did not relapse into heavy drinking
in comparison with 40% of the placebo treated subjects
[4]. In the laboratory setting, naltrexone has been shown
to increase the latency to drink alcohol in social drinkers
Published: 01 April 2005
BMC Psychiatry 2005, 5:18 doi:10.1186/1471-244X-5-18
Received: 05 October 2004
Accepted: 01 April 2005
This article is available from: http://www.biomedcentral.com/1471-244X/5/18
© 2005 Galloway et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Psychiatry 2005, 5:18 http://www.biomedcentral.com/1471-244X/5/18
Page 2 of 10
(page number not for citation purposes)
[6], to reduce drinking in heavy drinkers [7] and increase
certain discriminant and sedative effects of ethanol while
reducing the positive reinforcing effects of ethanol in non-
alcoholics [8].
While many single site studies and 2 meta-analyses [9,10]
indicate that naltrexone is more effective than placebo,
there have also been 2 multisite studies and 1 single site
study in which naltrexone was not found to be effective in
decreasing alcohol consumption [11-13].
One factor that appears to be important for naltrexone's
effectiveness is adherence. In 2 studies, oral naltrexone
was found to have an effect only in the population of
patients who were highly compliant with their medica-
tion [14,15]. Alcoholics have been shown to have particu-
larly low rates of medication adherence [16,17]. With
treatments intended to reduce or prevent relapse to alco-
hol or drug abuse, non-adherence has an additional
aspect. If a patient on naltrexone wants to resume drink-
ing or using drugs, they can discontinue their medication
and experience the full effect of the drug.
In alcoholics, an injectable sustained release formulation
(SRF) would be highly advantageous. A SRF of naltrexone
would reduce the number of opportunities to impulsively
discontinue their medication and ensure that discontinu-
ation came to the attention of the health care provider
scheduled to administer the injection. A SRF would mini-
mize the number of doses required and guarantee expo-
sure to the medication for at least the duration of the first
injection. It would have the added benefit of producing a
more consistent and predictable drug blood level since a
depot injection bypasses first pass metabolism [18].
Kranzler et al. [5] conducted a 12-week study of a different
depot formulation of naltrexone in 20 alcohol dependent
subjects. Subjects received either a subcutaneous injection
of 206 mg NTX (N = 15) or placebo (N = 5) along with
eight weekly coping skills sessions. Compared to placebo,
subjects who received the SRF of naltrexone had fewer
heavy drinking days. These initial results support the con-
tinuation of research into the use of a SRF of naltrexone in
patients being treated for alcohol dependence.
Comer et al. [19], evaluated the effectiveness, time course
and safety of the same naltrexone depot formulation used
in Kranzler's study [5], in 12 heroin dependent subjects
over an 8 week time span. The results from this study
showed that blood plasma levels remained above 1 ng/
mL for 3–4 weeks after receiving either 192 mg or 384 mg
of naltrexone depot. In this study there were few adverse
events reported other than the discomfort associated with
the actual injection of the depot formulation. It was
shown that the depot formulation of naltrexone at both
doses provided safe, effective and long lasting antagonism
of the effects of heroin.
The current study, a single site open-label study, was
designed to examine the safety, pharmacokinetics and tol-
erability of the DrugAbuse Sciences (DAS; Hayward, CA)
Naltrexone Depot formulation for treatment of alcohol
dependence. During the study, subjects received 1 depot




Sixteen subjects participated in this 6-week, single site,
open-label study to investigate the safety and tolerability
of Naltrexone Depot along with naltrexone and 6-beta-
naltrexol blood levels. The study was conducted at Friends
Research Associates in Berkeley, CA. All procedures were
approved by the Institutional Review Board of Friends
Research Institute.
Following initial screening, subjects were required to have
3 days of abstinence from alcohol. Subjects who tolerated
four days of oral naltrexone returned to the clinic the day
following their last dose of oral naltrexone and received
intramuscular injections of Naltrexone Depot containing
300 mg of naltrexone. See figure 1 for an outline of study
procedures.
Subjects
Subjects were recruited through advertising. Subjects were
males and non-pregnant, non-nursing females, age 18 to
65, with DSM-IV diagnoses of alcohol dependence who
expressed a desire to stop drinking. To meet inclusion cri-
teria, subjects had to have had at least 1 day of heavy
drinking (≥ 5 drinks/day for males or ≥ 4 drinks/day for
females) within the preceding 14 days. As noted above,
they had to be able to achieve at least three consecutive
days of sobriety, without detoxification medications.
Female subjects were required to practice effective birth
control for the duration of the trial and all subjects were
required to provide a urine sample negative for ampheta-
mines, barbiturates, benzodiazepines, cocaine and
opiates.
Subjects were excluded from the study if they were cur-
rently taking disulfiram, naltrexone or a neuroleptic med-
ication; if they needed medical detoxification from
alcohol; or if they had a DSM IV diagnosis of dependence
on any drug of abuse other than nicotine or alcohol. Sub-
jects were also excluded if they had an ALT or AST eleva-
tion more than 3 times the upper limit of normal or any
psychiatric condition (e.g., depression with suicidal idea-
tion) or medical condition that would preclude safeBMC Psychiatry 2005, 5:18 http://www.biomedcentral.com/1471-244X/5/18
Page 3 of 10
(page number not for citation purposes)
Study design of naltrexone depot in alcohol dependence Figure 1
Study design of naltrexone depot in alcohol dependence.
Table 1: Inclusion and Exclusion Criteria
Inclusion Criteria
• Males or non-pregnant, non-nursing females, age 18 to 65, with a DSM-IV diagnosis of alcohol dependence who express a desire to stop 
drinking.
• Heavy drinking (5 drinks/day for males or 4 drinks/day for females) within 14 days prior to randomization
• Able to achieve at least three continuous days of sobriety, without detoxification medications, immediately before beginning the oral 
naltrexone run-in dosing
• Willing and able to give informed consent
• Willing to practice effective birth control for duration of trial (female patients only)
• Available to participate in the study for 7 weeks
• Willing to provide names and permission to contact someone (e.g., spouse, parent, friend) who would likely know their whereabouts for 
follow-up tracking
• Naltrexone tolerance as demonstrated during run-in dosing period.
Exclusion Criteria
• Currently taking disulfiram (Antabuse), naltrexone (Revia or generic) or neuroleptic medication
• In need of medical detoxification from alcohol
• DSM-IV diagnosis of dependence on any drug of abuse other than nicotine or alcohol or drug screen showing benzodiazepines, marijuana, 
cocaine, methamphetamine, barbituates or heroin
• Clinical evidence of cardiac ischemia (by EKG or medical history) or history of myocardial infarction within the previous 2 years
• History of pancreatitis
• Planned surgery within 7 weeks of screening
• Any chronic or episodic painful conditions that would reasonably require opiate medications for pain control
• ALT or AST elevations more than 3 times the upper limit of normal
• Subjects with any psychiatric (e.g., depression with suicidal ideation) or medical condition that would preclude safe participation in the 
protocol.
• History of allergic or adverse response to naltrexone
• Participation in a trial of an investigational medication within 30 days prior to study enrollment
•Subjects mandated by court for alcohol or drug abuse treatment or having pending legal proceedings that could result in incarceration within 7 
weeks of screeningBMC Psychiatry 2005, 5:18 http://www.biomedcentral.com/1471-244X/5/18
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participation in the protocol. A complete list of inclusion
and exclusion criteria is presented in Table 1.
Study procedures
Before participation in study procedures began, prospec-
tive subjects had the study explained to them by a mem-
ber of the research team. The purpose of the study was
reviewed, and the potential risks and discomforts of study
participation were explained. Subjects were given a copy
of an informed consent form to read. Just prior to signing
the consent form a Breathalyzer test was performed; sub-
jects were not able to sign the consent unless their BAL
was less than 0.04 mg/dL. Following signing of the con-
sent form, a medical history and physical examination
were conducted to assess eligibility for study participa-
tion. In addition, subjects had an EKG performed along
with screening hematology, clinical chemistry, serum
pregnancy test (for women of childbearing age), urine tox-
icological screen and a routine urinalysis.
Following screening, subjects were administered one 50
mg naltrexone tablet at the clinic. Three additional tablets
were dispensed for the subjects to take on their own (1
each day for 3 days). Subjects then returned to the clinic
site the day following the final naltrexone dose. Subjects
who tolerated the oral naltrexone were eligible to partici-
pate in the study. The rationale for an oral naltrexone run-
in was to avoid exposing naltrexone intolerant individuals
to Naltrexone Depot, which once it is given cannot be
removed. Eligible subjects received 2 intramuscular injec-
tions of 150 mg of Naltrexone Depot, one in each buttock,
for a total dose of 300 mg.
Subjects then received brief counseling following their
injection and at each weekly study visit throughout the 6-
week trial. A therapist provided a manualized form of
counseling called BRENDA. BRENDA is an acronym for a
six step approach to counseling: Biopsychosocial evalua-
tion, Report to patient on assessment, Empathetic under-
standing of the patients problems, Needs expressed by the
patient which should be addressed, Direct advice on how
to meet those needs, and Assess response/behaviors of
patients to advise and adjust treatment recommendations.
BRENDA was chosen because, with treatment of alcohol
and drug abuse increasingly occurring in the context of
mainstream medical care, it is important to use brief
counseling therapies that are feasible within these settings
[20,21]. Subjects were permitted but not required to
attend Alcoholics Anonymous (AA) or other self-help
recovery programs.
Outcome measures
Each week, subjects were provided with a drinking diary.
In the diary, subjects were asked to record all of the alco-
holic drinks that they consumed and to return to clinic
with the completed diary each week. At each weekly visit,
the research assistant reviewed the diary with the subject
and recorded adverse events, service utilization and drink-
ing history. Timeline follow-back procedures were used
[22-25]. Using timeline follow-back procedures, the
number of standard drinks per day was recorded for each
day since the last visit. If a subject missed a data collection
visit, the timeline follow-back was extended to the last
visit attended. Subjects rated their maximum craving for
alcohol during the past week on a visual analog scale. The
research assistant also queried subjects about alcohol
craving and concurrent medications. Subjects had their
injection sites examined, a Breathalyzer test performed, a
blood draw taken and a urinalysis collected during each
weekly visit. The blood was analyzed for naltrexone and 6-
beta-naltrexol plasma levels along with GGT levels.
An LC-MS/MS method was used to determine plasma nal-
trexone and 6-beta-naltrexol levels simultaneously. A liq-
uid/liquid extraction under basic conditions was done
before injection into the LC-MS/MS. A PE Sciex API III+,
using an electrospray interface, was employed in this
study. Four analytical runs were required to process the
samples from this study. Naltrexone and 6-beta-naltrexol
analyses were performed by MDS Pharma Services, Lin-
coln, NE.
The linear range for naltrexone was 0.100 to 50.000 ng/
mL with a limit of quantitation of 0.100 ng/mL. Naltrex-
one quality control samples analyzed with each analytical
run had coefficients of variation less than or equal to
6.14% and absolute relative errors less than or equal to
7.67%. The linear range for 6-beta-naltrexol was 0.400 to
100.000 ng/mL with a limit of quantitation of 0.400 ng/
mL. 6-beta-naltrexol quality control samples analyzed
with each analytical run had coefficients of variation less
than or equal to 7.40% and absolute relative errors of less
than or equal to 7.70%.
Drinking measures were: drinking days (days on which
any drinking occurred), heavy drinking days (≥ 5 drinks/
day for men; ≥ 4 drinks/day for women) and drinks per
drinking day. These measures were cumulated for the 14-
day baseline period and for the 6 weeks following the nal-
trexone injection.
Alternate measures were generated for days on which
drinking data were not obtained after naltrexone was
administered. These missing days were counted as both
drinking days and heavy drinking days and the number of
drinks per drinking day were set equal to the mean
number of drinks per drinking day during the baseline
period. Analyses using these alternate measures did not
yield significantly different results and are not presented.BMC Psychiatry 2005, 5:18 http://www.biomedcentral.com/1471-244X/5/18
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Study medication
Naltrexone is a competitive antagonist at the mu opiate
receptor. Following oral administration naltrexone is
almost completely absorbed, but subject to first pass
metabolism; the bio-availability ranges from 5% to 60%
[26,27]). Naltrexone is primarily eliminated by the liver
with only 1% of an oral naltrexone dose excreted in urine
[28]. Conjugated and non-conjugated 6-beta-naltrexol are
the major metabolites found in plasma, urine and feces.
The half-life of elimination of parent naltrexone is 2.9
hours and 8.8 hours for 6-beta-naltrexol, which is a weak
antagonist at the mu opiate receptor [27,29].
Naltrexone Depot consists of microspheres of poly (D, L-
lactide) and naltrexone, administered by intra-muscular
injection. The microspheres are mixed with a diluent con-
taining water, mannitol, carboxymethylcellulose and
polysorbate 80 to form a suspension for injection. Once
injected, the suspension forms a solid gel pellet with the
rate of release proportional to the surface area of the gel
pellet, the loading of naltrexone in the microspheres and
the porosity of the microspheres. The polylactide poly-
mers are broken down to monomers by hydrolysis, releas-
ing naltrexone and ultimately being metabolized to
carbon dioxide and water.
Statistical analysis
Concentration-time data were analyzed by noncompart-
mental techniques using WinNonlinProfessional 3.1. The
pharmacokinetic parameters calculated were Cmax, tmax,
AUC0-t, AUC0-last, and the metabolite to parent AUC0-t
ratio.
Drinking data were analyzed using the univariate proce-
dure of SAS, version 8.2. Changes in liver function tests
were evaluated using a one-way analysis of variance com-
paring baseline values to end of study values.
Results
Subjects
Of the 17 subjects screened for study participation, 16
subjects (94.9%) met the inclusion/exclusion criteria and
received study medication. Of the 16 participating sub-
jects, 14 (87.5%) completed the study through week 6. Of
the 2 subjects (12.5%) who did not complete the study,
one subject was lost to follow-up while the other was
unwilling to complete the study due to the time required.
The mean age of the participants in the study was 49 years
with a range of 27–60 years. Thirteen (81%) of the sub-
jects were male and 10 (62.5%) of the subjects were Cau-
casian. Demographic and baseline clinical characteristics
are presented in Table 2.
Safety measures
As shown in Table 3, there was no significant difference
between patients' vital signs and liver function tests at the
beginning of the study and at the completion of the study.
Over the course of the study all 16 subjects had 1 or more
adverse events. A total of 15 subjects had injection site
adverse reactions. Table 4 shows the injection site adverse
events experienced by subjects in the study. Three subjects
experienced drainage from their injection site. The drain-
age fluid of 2 of the subjects was available for culture and
in both cases did not grow out any organisms. Of the 198
adverse events reported, 17 were rated severe: nausea, flat-
ulence, gastrointestinal pain, fatigue, lethargy, somno-
lence (2 reports), depression, irritability, headache (4
reports from 3 subjects), back pain, injection site mass,
injection site pain and elevated GGT. There were no seri-
ous averse events. As shown in Table 5, there were 13
reported changes in biochemical markers that were out-
side of normal ranges.
Drinking measures
All measures of drinking declined from the baseline
period to the 6-week treatment period: proportion of
drinking days from 0.77 (s.d. 0.25) to 0.46 (0.33) (signed
rank; S = -47.5, p = 0.0044), drinks per drinking day from
8.4 (s.d. 3.5) to 4.9 (s.d. 3.4) (S = -64, p = 0.0002) and
proportion of heavy drinking days from 0.58 (s.d. 0.27) to
0.25 (s.d. 0.27) (S = -56, p = 0.0004).
Pharmacokinetics
The pharmacokinetic results are based on weekly plasma
sampling for six weeks on day 0, 7, 14, 21, 28, 35 and 42
following the single dose administration of 300 mg (2 ×
150 mg) Naltrexone Depot. On Day 0 blood samples were
drawn prior to dosing of Naltrexone Depot. Pre-dose con-
centrations reflect naltrexone and 6-beta-naltrexol plasma
Table 2: Baseline Demographic and Clinical Characteristics
Characteristic









DSM-IV Alcohol Dependence Criteria Met, mean (SD) 5.4 (0.7)
Baseline Heavy Drinking Days, mean (SD) 10.9 
(3.5)
Baseline Drinks Per Drinking Day, mean (SD) 8.4 (3.5)
Baseline Heavy Drinking Days, mean (SD) 8.1 (3.8)BMC Psychiatry 2005, 5:18 http://www.biomedcentral.com/1471-244X/5/18
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concentrations following multiple administration of 50
mg naltrexone oral tablets from study days -4 through -1,
which were not expected to influence levels in subsequent
samples. Pre-dose plasma concentrations on day 0 were
set to O for the calculation of AUCs and were excluded
from the reporting of tmax. For naltrexone, mean (range)
Cmax value was 2.640 (0.57–11.02) ng/mL. Values for tmax
were variable and ranged from 168 hr to 1,008 hr
(median: 540 hr) post-dose. In terms of exposure, mean
(range) values for AUC0–28 and AUC 0–42 were 829 (149–
3,332) ng/hr/mL and 1089 (341–3899) ng/hr /mL,
respectively. For the major metabolite, 6-beta-naltrexol,
the mean (range) Cmax value was 8.71 (0.99–41.13) ng/
mL. Values for tmax  ranged from 168 hr to 1,008 hr
(median: 336 hr). The mean 6-beta-naltrexol to naltrex-
one ratios were 3.5 for AUC0–28 and 3.4 for AUC0–42. The
Table 3: Vital Signs and Liver Function Tests
Parameter Pre-Treatment (= day -7) mean ± sd Post-Treatment (last visit) mean ± sd
Number of Patients 16 14
Systolic Blood Pressure, mm Hg 135 ± 13 132 ± 10
Diastolic Blood Pressure, mm Hg 85 ± 9 83 ± 6
Pulse, beats/min 80 ± 5 79 ± 9
AST, IU/L 31.9 ± 14.6 27.6 ± 22.7
Total Bilirubin, mg/dL 0.6 ± 0.3 0.6 ± 0.3
Table 4: Adverse Injection Site Events
Adverse Event* Mild Moderate Severe
Bruising 2 0 0
Inflammation 1 1 0
Mass 3 3 1
Pain 3 6 1
Pigmentation Change 2 1 0
Site Reaction NOS 2 1 0
*All values, N (%)
Table 5: Laboratory Value Abnormalities
Adverse Event % Reporting Adverse Event
Blood Lactate Dehydrogenase Increased 31.3
Gamma-Glutamyl Transferase Increased 18.8
Red Blood Cells Present In Urine 12.5
Proteinuria Present 12.5
Alanine Aminotransferase Increased 12.5
Blood Creatine Increased 12.5
Hemoglobin Decreased 12.5
Hematocrit Decreased 6.3
Lymphocyte Count Decreased 6.3
Neutrophil Count Increased 6.3
Protein Total Increased 6.3
Aspartate Aminotransferase Increased 6.3
Uric Acid Increased 6.3
Urine Analysis Abnormal NOS 6.3
White Blood Cell Count Increased 6.3
White Blood Cells In Urine 6.3BMC Psychiatry 2005, 5:18 http://www.biomedcentral.com/1471-244X/5/18
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mean (range) values for AUC0–28 and AUC0–42 were 2528
(606–8872) ng/hr/mL and 3286 (988–8872) ng/hr/mL,
respectively. Plasma concentrations of 6-beta-naltrexol
were approximately 3-fold higher than naltrexone at all
sampling times.
Fourteen (88%) subjects had detectable plasma concen-
trations of naltrexone at 42-days post-dose, 1 (6%) sub-
ject had a detectable concentration at their last visit 35-
days post-dose and 1 (6%) subject had a detectable con-
centration at their last visit 14-days post-dose. The mean
concentrations of naltrexone ranged from 0.58 ng/mL to
2.04 ng/mL at each sampling time after administration;
see Figure 3
Thirteen (81%) subjects had detectable 6-beta-naltrexol
concentrations at 42-days post-dose, 1 (6%) subject had a
detectable concentration at their last visit 35-days post-
dose, 1 (6%) subject had a detectable concentration at
their last visit 14-days post-dose and 1 subject had a
detectable concentration through 28 days post dose, after
which 6-beta-naltrexol was undetectable. The mean con-
centrations of 6-beta-naltrexol ranged from 1.51 ng/mL to
5.52 ng/mL at each sampling time after administration;
see Figure 4.
Discussion
The results from this 6-week, single site, open-label study
to investigate the safety and pharmacokinetics of Naltrex-
one Depot showed it to be safe, well tolerated and led to
sustained plasma levels of naltrexone. The overall comple-
tion rate for study participants was 88%. The 2 subjects
who did not complete the study were not lost because of
adverse effects.
Injection site complications were by far the most common
side effect experienced by subjects participating in this
study. Of the side effects experienced the most severe were
drainage from the injection site. In the absence of any evi-
dence of infection and given the history of inflammatory
reactions from naltrexone injections [30], these cases of
drainage were determined to have been caused by a local
inflammatory reaction. Although this rate of drainage was
concerning, it is important to note that none of the sub-
jects required hospitalization, the drainage was self limit-
ing, and the subjects were remarkable unconcerned about
it. Other common side effects were gastrointestinal, nerv-
ous system, and changes in metabolic markers, but these
occurred at a similar rate as in other naltrexone trials in
alcohol and heroin dependent subjects [5,11,31].
Serum Naltrexone Levels Figure 3
Serum Naltrexone Levels.BMC Psychiatry 2005, 5:18 http://www.biomedcentral.com/1471-244X/5/18
Page 8 of 10
(page number not for citation purposes)
The mean plasma concentration across all sampling times
ranged from 0.12 ng/mL to 2.04 ng/mL. On the last sam-
pling day (day 42) all subjects available for testing had
detectable plasma concentrations of naltrexone. These
results are encouraging and show that the depot formula-
tion of naltrexone can provide plasma concentrations of
active drug for over 30 days. For a depot formulation of
naltrexone to be accepted in clinical practice, a duration of
action of at least 1 month is probably necessary [32]. This
is the case because it limits the number of visits a patient
has to make to their health care provider and limits the
number of injections they must receive. Although detecta-
bility for the study duration is important, further informa-
tion is needed on what constitutes an optimal level.
Plasma levels of 6-beta-naltrexol were 3 times higher than
naltrexone levels at all sampling times. When naltrexone
is administered through the IM route it bypasses 1st pass
metabolism, which leads to a lower ratio of 6-beta-nal-
trexol to naltrexone [33]. It is still unclear how much 6-
beta-naltrexol contributes to the efficacy and adverse
effects of Naltrexone Depot, but the lower ratio of 6-beta
naltrexol to naltrexone may reduce adverse effects which
are due to the 6-beta-naltrexol. In a preliminary study
looking at the relationship between 6-beta naltrexol levels
and the incidence of subjective side effects following oral
administration of 50 mg of naltrexone, subjects who expe-
rienced more side effects had significantly higher urinary
levels of 6-beta-naltrexol [33,34]. These side effects
included headache, nausea, anxiety and spontaneous
erection. Overall, subjects had a 10:1 urinary ratio of 6-
beta-naltrexol to naltrexone. It has been suggested that 6-
beta-naltrexol contributes to the continuing antagonism
of heroin's effects due to the fact that its blood levels are
consistently higher than naltrexone's after depot adminis-
tration [19]. The pharmacological properties and activity
of 6-beta-naltrexol need to be investigated further before
a definitive answer can be given on the role of 6-beta-nal-
trexol in its ability to modulate the response to alcohol
and heroin.
Subjects participating in this study experienced a decrease
in drinking days, drinks per drinking day, and heavy
drinking days. These results are consistent with the study
by Kranzler [5](1998) using a different depot formulation
of naltrexone. In that study there was a clinically signifi-
cant effect on the frequency of heavy drinking days. The
results from these 2 studies provide the foundation for
large multi-site studies on the efficacy and safety of Nal-
trexone Depot.
6-beta-Naltrexol Levels Figure 4
6-beta-Naltrexol Levels.BMC Psychiatry 2005, 5:18 http://www.biomedcentral.com/1471-244X/5/18
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Limitations of this study include the fact that this it was
small, single site, open-label, and the sample is primarily
older and male. The lack of a placebo group makes it dif-
ficult to assess the contribution of Naltrexone Depot to
the reduction in drinking. Nonetheless, the results from
this open-label study are encouraging and warrant further
evaluation of Naltrexone Depot as a treatment option for
alcohol dependent patients. Approaches such as this that
optimize adherence have the potential to maximize the
efficacy of naltrexone in the treatment of alcohol
dependence.
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